Related Experiment Videos
Pharmacologic interventions for type 1 and type 2 diabetes.
1College of Nursing, University of Massachusetts Dartmouth, North Dartmouth, MA 02747-2300, USA. jfain@umassd.edu
The Nursing Clinics of North America
|October 25, 2006
Summary
This review updates pharmacologic interventions for type 1 and type 2 diabetes, covering drug classes, new therapies like incretin mimetics, and combination treatments for better blood sugar control.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Diabetes mellitus (type 1 and type 2) is a global health concern requiring effective pharmacologic management.
- Numerous drug classes exist, necessitating regular updates on their efficacy, safety, and application.
Purpose of the Study:
- To provide a comprehensive update on pharmacologic interventions for diabetes.
- To discuss current drug classifications, including background, dosing, and side effects.
- To review combination therapy and introduce novel therapeutic classes.
Main Methods:
- Literature review of pharmacologic interventions for diabetes.
- Analysis of drug classifications, mechanisms of action, and clinical data.
- Inclusion of information on new drug classes: incretin mimetics and antihyperglycemics.
Main Results:
- Detailed overview of established pharmacologic classes for diabetes treatment.
- Discussion of combination therapy strategies for optimized glycemic control.
- Introduction to incretin mimetics and antihyperglycemics as emerging treatment options.
Conclusions:
- Pharmacologic interventions are crucial for managing type 1 and type 2 diabetes.
- An updated understanding of drug classes, combination therapies, and new agents is essential for clinicians.
- Incretin mimetics and antihyperglycemics represent significant advancements in diabetes pharmacotherapy.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...